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Maculopathy in
Dengue Fever
To the Editor: A recent article by
Chlebicki et al (1) described 4 patients
hospitalized for dengue fever who
were found to have retinal hemor-
rhages. These patients reported
reduced visual acuity and metamor-
phopsia, i.e., distorted visual images
attributable to intrinsic retinal disease
involving the macula; macular hemor-
rhages and exudates were found on
retinal examination. The authors con-
cluded that the retinal hemorrhages
were responsible for the patients’
visual symptoms.
This conclusion is misleading
because retinal hemorrhages alone
cause scotomas. Rather, the accumu-
lation of subretinal fluid in the macu-
la results in metamorphopsia and
blurring of vision. In previous reports
of patients in whom macular changes
developed from dengue fever, some
were found to have macular hemor-
rhages (2–4). In addition, clinical
examination and investigation of
these patients showed vasculopatho-
logic changes in the macular region
that affected the retinal and choroidal
blood vessels (5), although the tissues
of the periphery tended to be spared.
A fluorescein angiograph of the retina
showed knobby hyperfluorescence of
the retinal arterioles with minimal
leakage, as well as some spots of leak-
age at the level of the retinal pigment
epithelium. An indocyanine green
angiograph showed diffuse hyperfluo-
rescence of the choroid. These patho-
logic changes in the macula were the
most likely cause of the blurring of
vision in such patients, which has
been the case in our experience.
The article by Chlebicki et al. did
not state whether these procedures
had been performed on their patients
to confirm or exclude retinal or
choroidal vasculopathy in the macula.
Therefore, these authors would have
had difficulty concluding that retinal
hemorrhages caused blurring of
vision and metamorphopsia in
patients with dengue maculopathy.
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Pulmonary
Tuberculosis and
SARS, China 
To the Editor: As part of a cohort
study of 83 patients with severe acute
respiratory syndrome (SARS) in
Beijing, China, we conducted a fol-
low-up study of all the patients by
routine medical examination. During
the process, 3 patients with chest radi-
ographs consistent with active disease
were identified as having pulmonary
tuberculosis (TB). Here we describe
the 1-year clinical outcome and
immune response in these patients. 
Demographic details and coexist-
ing conditions are shown in the Table.
Patient 1 was a healthcare worker who
became infected with SARS-associat-
ed coronavirus (CoV) while on duty
with SARS patients. After he was
transferred to a hospital dedicated to
SARS management, pulmonary TB
was diagnosed (positive acid-fast
bacilli smear on sputum samples).
Patients 2 and 3 were known to have
cases of pulmonary TB and became
infected with SARS-CoV after con-
tact with other patients hospitalized
for SARS. These 2 patients were spu-
tum smear–negative for acid-fast
bacilli, and diagnosis was made on the
basis of previous exposure to TB, rel-
evant symptoms of typical pulmonary
TB, chest radiographs consistent with
active disease, a positive tuberculin
skin test result, and the finding of cav-
ity regression on chest radiographs
after anti-TB treatment was initiated.
No cultures were obtained for isola-
tion and comparison of Myco-
bacterium tuberculosis strains (1). All
3 patients had confirmed SARS based
on amplification of SARS-CoV RNA
by reverse transcriptase–polymerase
chain reaction (RT-PCR) from sputum
and stool specimens (2). Patients 2
and 3 recovered without complica-
tions; patient 1 had the most severe
disease and required mechanical ven-
tilation in an intensive care unit before
recovering.
Both cellular and humoral immu-
nity were evaluated during the follow-
up of these patients. T-lymphocyte
subsets were measured 6 months after
disease onset by flow cytometry using
fluorescein isothiocyanate–labeled
specific monoclonal antibodies.
Compared to other SARS patients (n
= 47), the 3 patients with TB had
lower mean CD4+ T cells (368.4/µL
vs. 656.6/µL, respectively; p = 0.05)
and lower mean CD8+ T cells
(371.0/µL vs. 490.1/µL, respectively;
p = 0.39). SARS-CoV immunoglobu-LETTERS
lin G (IgG) antibody titers were meas-
ured by enzyme-linked immunosor-
bent assay kit (Huada Company,
Beijing, China) at months 1, 2, 3, 4, 7,
10, and 16 after disease onset. (Titers
were not measured for the 3 TB
patients at month l.) Compared to
most (26 [78.8%] of 33) other SARS
patients whose antibodies remained
detectable throughout follow-up, 2 of
the 3 TB patients (patients 1 and 3)
had undetectable antibody titers as of
months 7 and 16, respectively. In
patient 1, antibody titers, when
detectable, were unusually low (40).
Both patients 1 and 3 had prolonged
viral excretion in stools, sputum, or
both. While the median (range) dura-
tion of virus excretion in stools and
sputa for the entire measurable cohort
(n = 56) was 27 (16–127) and 21
(14–52) days, respectively (3), it was
125 and 16 days for patient 1, and 109
and 52 days for patient 3 (viral excre-
tion data could not be obtained from
patient 2 because sequential speci-
mens for detection were unavailable). 
TB in SARS patients has been
reported on rare occasions (4,5). In a
cohort of 236 patients in Singapore, it
was diagnosed in 2 patients after
recovery from SARS (4). As with
patient 1 in this study, TB had devel-
oped after the patient acquired SARS,
most likely as the result of reactiva-
tion of past infection or new infection
with M. tuberculosis, while temporar-
ily immunosuppressed because of
SARS (6) and corticoid therapy. Such
phenomena have been described with
other viral infections such as measles
and HIV (7,8). By contrast, patients 2
and 3 were known TB patients who
acquired SARS through exposure to
SARS patients in the same hospital
wards. Both diseases are known to be
transiently immunosuppressive (6,9),
and their combined effect resulted in
more pronounced CD4+ cell decreas-
es in coinfected SARS patients than
others. Such immunosuppression also
resulted in poorer IgG antibody
response in coinfected SARS patients
than in others and delayed viral clear-
ance, as shown by longer viral excre-
tion in sputum and stools. While viral
excretion could be prolonged in coin-
fected patients, no virus could be iso-
lated from any RT-PCR–positive
specimen collected after 6 weeks of
illness, which suggests that excreted
viruses were no longer infectious (3).
These case reports remind us of the
importance of strict isolation of SARS
patients, careful use of steroids for
their case management, and the possi-
bility of coinfection with TB in SARS
patients with incomplete recovery.
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Tetanus in
Injecting Drug
Users, United
Kingdom
To the Editor: The epidemiology
of tetanus in the United Kingdom
changed in 2003 when a cluster of
cases in injecting drug users (IDUs)
occurred (1,2). Before 2003, the inci-
dence of tetanus was low in the
United Kingdom, with occasional
cases predominantly in unvaccinated
elderly persons (3). The situation con-
trasted with the United States where
injecting drug use is commonly
reported among persons with tetanus
(4).
We investigated the UK cluster to
identify the source of infection and
opportunities for prevention. We
ascertained cases through statutory
and nonstatutory reporting to the
Health Protection Agency and collect-
ed additional information on IDUs for
all reported cases of tetanus since
January 1, 2003, by adapting the
existing enhanced tetanus surveil-
lance. A case was defined as mild-to-
moderate trismus and at least 1 of the
following: spasticity, dysphagia, res-
piratory embarrassment, spasms,
autonomic dysfunction, in a person
who injected drugs in the month
before symptom onset. 
Twenty-five cases were reported
from July 2003 to September 2004
(Figure). Thirteen (50%) were
women; the median age of male and
female patients was 39 and 32 years
of age, respectively (range 20–53, p =
0.1). Twenty patients were white, and
1 was Chinese (information was miss-
ing for 4). None reported travel over-
seas before becoming sick. Seventeen
of 21 patients with information
reported having injected heroin intra-
muscularly or subcutaneously (pop-
ping) or having missed veins. Most
patients (16/25) came to the hospital
with severe generalized tetanus.
Injection site infections were common
(17/19). 
Two patients died (case fatality
8%). Of 23 survivors, 2 had mild dis-
ease and 21 required intensive treat-
ment for a median of 40 days (range
24–65 in 15 cases with complete infor-
mation). Tetanus immunization status
available for 20 case-patients (based
on medical records or patient and
parental recall) indicated that only 1
patient (with severe disease) had
received the 5 doses necessary for
complete coverage. Nine patients were
never vaccinated. Twelve of 14
patients tested for tetanus immunity on
admission by a standard indirect
enzyme-linked immunosorbent assay
had antibody levels lower than the cut-
off value for protection (<0.1 IU/mL).
One patient with severe disease had a
level just above the cutoff value and 1
patient with mild disease had a protec-
tive antibody level. Clostridium tetani
was isolated from 2 patients; tetanus
toxin was detected in serum from 1
and also from another patient. Other
anaerobes, including C. novyi, C. his-
tolyticum, and C. perfringens, were
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Figure. Cases of tetanus in injecting
drug users by residence (25 cases) and
place from which heroin was supplied
(14 cases with information), United
Kingdom, July 2003–September 2004.
The large circle indicates the Liverpool
area. Squares indicate the residence of
patients for whom the origin of heroin
was not reported, open circles indicate
the residence of patients for whom the
origin of heroin was reported, and solid
circles indicate the origin of heroin.